Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Jun;6(6):708-20.
doi: 10.1002/emmm.201403876. Epub 2014 Apr 6.

Vaccines for the 21st century

Affiliations
Review

Vaccines for the 21st century

Isabel Delany et al. EMBO Mol Med. 2014 Jun.

Abstract

In the last century, vaccination has been the most effective medical intervention to reduce death and morbidity caused by infectious diseases. It is believed that vaccines save at least 2-3 million lives per year worldwide. Smallpox has been eradicated and polio has almost disappeared worldwide through global vaccine campaigns. Most of the viral and bacterial infections that traditionally affected children have been drastically reduced thanks to national immunization programs in developed countries. However, many diseases are not yet preventable by vaccination, and vaccines have not been fully exploited for target populations such as elderly and pregnant women. This review focuses on the state of the art of recent clinical trials of vaccines for major unmet medical needs such as HIV, malaria, TB, and cancer. In addition, we describe the innovative technologies currently used in vaccine research and development including adjuvants, vectors, nucleic acid vaccines, and structure-based antigen design. The hope is that thanks to these technologies, more diseases will be addressed in the 21st century by novel preventative and therapeutic vaccines.

Keywords: adjuvants; clinical trials; infectious diseases; structural vaccinology; vectors.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Major milestones in the historical path of the development of vaccinology and vaccine design
A method for preventing naturally acquired smallpox called ‘variolation’ was discovered in India before 1,000 A.D. and was in use also in China and Western Asia. This method, which consisted of the inoculation of pustule material from smallpox-infected patients to healthy individuals, was introduced in Europe in 1,721 by Lady Mary Wortley Montagu. The first real vaccination practice was introduced when Edward Jenner used pustule material from humans infected by cowpox to protect against smallpox.
Figure 2
Figure 2. Target disease and target populations for 21st century vaccine development
Included in the list are the agents of infectious diseases for which vaccines are not yet available or for which more effective vaccines would be beneficial. Also included are therapeutic vaccines for chronic infectious diseases, as well as non-communicable pathologies such as autoimmune diseases, cancer, and allergy, some of which are in advanced clinical trials.
Figure 3
Figure 3
The 21st century vaccinologists toolbox

Similar articles

Cited by

References

    1. Agnandji ST, Lell B, Soulanoudjingar SS, Fernandes JF, Abossolo BP, Conzelmann C, Methogo BG, Doucka Y, Flamen A, Mordmuller B, et al. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Eng J Med. 2011;365:1863–1875. - PubMed
    1. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006;124:783–801. - PubMed
    1. Back JW, Langedijk JP. Structure-based design for high-hanging vaccine fruits. Adv Immunol. 2012;114:33–50. - PubMed
    1. Bagarazzi ML, Yan J, Morrow MP, Shen X, Parker RL, Lee JC, Giffear M, Pankhong P, Khan AS, Broderick KE, et al. Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses. Sci Transl Med. 2012;4:155ra138. - PMC - PubMed
    1. Barouch DH, Whitney JB, Moldt B, Klein F, Oliveira TY, Liu J, Stephenson KE, Chang HW, Shekhar K, Gupta S, et al. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature. 2013;503:224–228. - PMC - PubMed